Shield Therapeutics has today announced the refinancing of its current term debt and, correspondingly, secured improved terms with its current debt provider, SWK. As a consequence, this has enabled Shield to lower its debt-related costs and furthermore to access up to $30m of additional capital to provide further flexibility for future growth opportunities, including, as noted in this morning’s release, potential future M&A. On this basis, today’s news reflects current available funds of up to $ ....
